Related Experiment Video

Updated: May 10, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Correlation of miR-214, miR-204, miR-25, miR-15a Expression with IL-33 and Malondialdehyde in Blood Samples from

Haydar Sahib Almawashee1, Mohammad Khalaj-Kondori1, Mohammad Ali Hosseinpour Feizi1

  • 1Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

Microrna (Shariqah, United Arab Emirates)
|January 27, 2026
PubMed
Abstract

Insights

MicroRNAs (miRNAs) and IL-33 levels, along with Malondialdehyde (MDA) plasma levels, are altered in Alzheimer's disease (AD). These biomarkers show potential for AD diagnosis and understanding disease development.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Alzheimer's disease (AD) is a prevalent neurodegenerative disorder.
  • MicroRNA (miRNA) dysregulation is implicated in AD pathogenesis.
  • miRNAs may serve as diagnostic and prognostic biomarkers for AD.

Purpose of the Study:

  • To investigate the expression levels of miR-214, miR-204, miR-15a, and miR-25 in AD patients.
  • To explore correlations between these miRNAs, IL-33 expression, plasma Malondialdehyde (MDA) levels, and Mini-Mental State Examination (MMSE) scores.
  • To assess the potential of these molecules as biomarkers for AD.

Main Methods:

  • Case-control study involving 75 AD patients and 50 healthy controls.
  • Quantification of plasma MDA using ELISA.
  • RNA extraction from blood lymphocytes for qRT-PCR analysis of miRNA and IL-33 expression.

Main Results:

  • Downregulation of miR-15a, miR-25, and IL-33; upregulation of miR-214 and miR-204 observed in AD patients.
  • Significantly higher plasma MDA levels in AD patients.
  • ROC curve analysis indicated that the studied miRNAs, IL-33, and MDA effectively differentiate AD patients from controls.

Conclusions:

  • Expression levels of miR-214, miR-204, miR-15a, miR-25, IL-33, and plasma MDA are deregulated in AD.
  • These molecules show potential as biomarkers for AD development and diagnosis.
Keywords:
Alzheimer’s diseaseCytokine.Gene expressionInterleukin-33MalondialdehydemiRNA

More Related Videos

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy07:45

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Published on: December 30, 2025

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...